4.6 Article

The burden of neuropathic pain: A systematic review and meta-analysis of health utilities

期刊

PAIN
卷 149, 期 2, 页码 338-344

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1016/j.pain.2010.02.034

关键词

Neuropathic pain; Utility; Health-related quality of life; Meta-analysis; EQ-5D

资金

  1. Medtronic, Inc
  2. Analgesic Research
  3. Consultants in Behavioral Research
  4. Endo Pharmaceuticals
  5. Fralex Therapeutics, Inc.
  6. Merck Co., Inc.
  7. National Multiple Sclerosis Society
  8. Pfizer, Inc.
  9. US Department of Education
  10. US Department of Veterans Affairs
  11. US National Institutes of Health
  12. Boehringer
  13. Astra Zeneca
  14. Eli Lily
  15. Schering Plough
  16. GlaxoSmithKline

向作者/读者索取更多资源

Patients with neuropathic pain (NeuP) experience substantially lower health-related quality of life (HRQoL) than the general population. The aim of this systematic review and meta-analysis is to test the hypothesis that NeuP is associated with low levels of health utility. A structured search of electronic databases (MEDLINE, EMBASE, Cochrane Library and CINAHL) was undertaken. Reference lists of retrieved reports were also reviewed. Studies reporting utility single-index measures (preference based) in NeuP were included. Random effects meta-analysis was used to pool EQ-5D index utility estimates across NeuP conditions. The association of utilities and pre-defined factors (NeuP condition, patient age, sex, duration and severity of pain and method of utility scoring) was examined using meta-regression. Twenty-four studies reporting health utility values in patients with NeuP were included in the review. Weighted pooled utility score across the studies varied from a mean of 0.15 for failed back surgery syndrome to 0.61 for post-herpetic neuralgia and diabetic neuropathy. Although there was substantial heterogeneity (P < 0.0001) across studies, we found little variation in utility as a function of patient and study characteristics. The single exception was a significant relationship (P < 0.0001) between increasing neuropathic pain severity and a reduction in utility. This study confirms the hypothesis that patients with NeuP experience low utilities and therefore low HRQoL. However, the contribution of non-NeuP co-morbidity remains unclear. Neuropathic pain severity emerged as a primary predictor of the negative health impact of NeuP. (C) 2010 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据